Frequency Therapeutics Inc., of Woburn, Mass., was awarded a $2 million grant from the U.S. Department of Defense to support the development of its small-molecule drugs to treat hearing dysfunction that are designed to awaken dormant progenitor cells in the ear that can induce the regeneration of hair cells and neuronal connections.